Accolade And 2 Other Penny Stocks To Watch On US Exchanges

In This Article:

As major U.S. indexes experience a downturn, driven by disappointing earnings reports from big tech companies, investors are exploring alternative opportunities in the market. Penny stocks, often representing smaller or newer companies, continue to attract attention despite their vintage label. These stocks can offer surprising value and growth potential when backed by strong financials, making them an intriguing option for those seeking under-the-radar investment opportunities.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.799

$5.75M

★★★★★★

LexinFintech Holdings (NasdaqGS:LX)

$3.19

$534.34M

★★★★★★

RLX Technology (NYSE:RLX)

$1.63

$2.12B

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.575

$50.82M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71M

★★★★★★

MIND C.T.I (NasdaqGM:MNDO)

$1.88

$39.56M

★★★★★★

ARC Document Solutions (NYSE:ARC)

$3.41

$147.91M

★★★★★★

Commercial Vehicle Group (NasdaqGS:CVGI)

$3.01

$99.68M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$1.10

$98.93M

★★★★★☆

So-Young International (NasdaqGM:SY)

$1.25

$97.93M

★★★★☆☆

Click here to see the full list of 756 stocks from our US Penny Stocks screener.

Let's take a closer look at a couple of our picks from the screened companies.

Accolade

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Accolade, Inc. develops and provides personalized, technology-enabled solutions to help individuals navigate the healthcare system and workplace benefits in the United States, with a market cap of approximately $265.77 million.

Operations: Accolade's revenue is primarily derived from its Pharmacy Services segment, totaling $441.03 million.

Market Cap: $265.77M

Accolade, Inc. operates with a market cap of approximately US$265.77 million and has shown revenue growth, reporting US$106.36 million in sales for the second quarter of 2024, up from the previous year. Despite being unprofitable with a net loss of US$23.93 million for the same period, its short-term assets exceed both short and long-term liabilities, indicating financial resilience. The company is trading at a significant discount to estimated fair value and has sufficient cash runway for over three years based on current free cash flow trends. However, shareholders have faced dilution recently as shares outstanding increased by 5.6%.

NasdaqGS:ACCD Financial Position Analysis as at Oct 2024
NasdaqGS:ACCD Financial Position Analysis as at Oct 2024

Accuray

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for tumor treatment across various global regions, with a market cap of approximately $186.51 million.

Waiting for permission
Allow microphone access to enable voice search

Try again.